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Abstract
Platelets are critical for hemostasis, i.e. the body's ability to prevent blood loss at sites of vascular 
injury. They patrol the vasculature in a quiescent, non-adhesive state for approximately 10 days, 
after which they are removed from circulation by phagocytic cells of the reticulo-endothelial 
system. At sites of vascular injury, they promptly shift to an activated, adhesive state required for 
the formation of a hemostatic plug. The small GTPase RAP1 is a critical regulator of platelet 
adhesiveness. Our recent studies demonstrate that the antagonistic balance between the RAP1 
regulators, CalDAG-GEFI and RASA3, is critical for the modulation of platelet adhesiveness, 
both in circulation and at sites of vascular injury. The RAP1 activator CalDAG-GEFI responds to 
small changes in the cytoplasmic calcium concentration and thus provides sensitivity and speed to 
the activation response, essential for efficient platelet adhesion under conditions of hemodynamic 
shear stress. The RAP1 inhibitor RASA3 ensures that circulating platelets remain quiescent by 
restraining CalDAG-GEFI-dependent RAP1 activation. Upon cellular stimulation, it is turned off 
by P2Y12 signaling to enable sustained RAP1 activation, required for the formation of a stable 
hemostatic plug. This review will summarize important studies that elucidated the signaling 
pathways that control RAP1 activation in platelets.
Introduction
Platelets are highly specialized blood cells evolved to secure the integrity of the 
cardiovascular system over a broad range of hemodynamic shear conditions[1]. Inhibitory 
signaling pathways ensure that platelets remain in a quiescent (non-adhesive) state as long as 
the endothelial lining is physically and biochemically intact. At sites of vascular injury, 
platelets employ Immunoreceptor Tyrosine-based Activation Motif (ITAM)-coupled 
receptors and G Protein-Coupled Receptors (GPCRs) to sense and respond to changes in 
their environment, such as the exposure of extracellular matrix (ECM) proteins and the 
activation of the coagulation system. Stimulation of these receptors triggers intracellular 
signaling cascades[2], including those dependent on elevated cytosolic calcium (Ca2+), 
which promote dramatic cytoskeletal changes, the secretion of granules and, most 
importantly, the conversion of integrins from a low- to a high-affinity state for their ligands 
(integrin inside-out activation) [3]. Integrins are the main platelet receptors that support 
platelet-matrix (platelet adhesion) and platelet-platelet interactions (platelet aggregation). 
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αIIbβ3 integrin is by far the most abundant of the β1 integrins and β3 integrins expressed on 
the platelet surface. It facilitates the binding of various plasma proteins, including fibrinogen 
and von Willebrand factor (VWF), and it is crucial for platelet adhesion and aggregation. 
The formation of a stable hemostatic plug or a pathological thrombus requires sustained 
integrin inside-out activation, provided by co-stimulatory signaling via the autocrine/
paracrine agonists thromboxane (Tx)A2 and ADP[4, 5]. ADP is released from platelet dense 
granules and supports sustained integrin activation by binding to the Gi-coupled receptor, 
P2Y12, the target of currently used anti-platelet drugs[6]. Studies by us and others identified 
a critical role for the small GTPase RAP1B in platelet activation and integrin-mediated 
cellular adhesion. This review will discuss how RAP1B and its known regulators, CalDAG-
GEFI and RASA3, ensure that platelet integrin activation is rapid, sustained and tightly 
controlled.
RAP1 GTPases and platelet activation
Approximately 8% of the known proteins expressed in platelets are small GTPases and their 
regulators[7, 8]. The most abundant GTPases in platelets are two isoforms of the Ras-related 
protein (RAP) subfamily, RAP1B (~300,000 copies/platelet) and RAP1A (~125,000 copies/
platelet). Like other small GTPases of the Ras superfamily, RAP proteins are molecular 
switches that cycle between an inactive GDP-bound state and an active GTP-bound state. 
Two classes of regulatory proteins control this switch. Guanine nucleotide exchange factors 
(GEFs) promote the activation by stimulating the exchange of GDP for GTP, and GTPase-
activating proteins (GAPs) terminate the activation by catalyzing GTP hydrolysis[9].
In platelets, GTP-loading of RAP1 is stimulated by all known agonists[10, 11]. Upon 
engagement of agonist receptors, RAP1 translocates from the cytosolic leaflet of 
intracellular granules, where it is sequestered in resting platelets, to the plasma 
membrane[12, 13]. Activated RAP1 regulates multiple functional responses in platelets, 
most notably integrin activation [14, 15]. Genetic deletion in mice of the predominant RAP1 
isoform, RAP1B, or inactivation of the main pathways leading to RAP1 activation markedly 
impaired integrin inside-out[15, 16] and outside-in[17, 18] signaling, granule secretion[18, 
19], TxA2 generation[20], spreading[18, 19] and clot retraction[18, 19]. Consistent with the 
defective platelet activation response, these mice exhibited significantly prolonged bleeding 
times and a strong protection from experimental thrombosis[15, 21].
CalDAG-GEFI: a critical RAP-GEF and accelerator of platelet activation
Pharmacological and genetic studies at the turn of the century demonstrated that two 
kinetically distinct pathways regulate RAP1 activation in platelets. Rapid RAP1 activation is 
triggered by an increase in intracellular Ca2+ concentrations[10], while sustained RAP1 
activation requires signaling by protein kinase C (PKC)[22], the Gi-coupled receptor for 
ADP, P2Y12, and phosphatidylinositol 3-kinases (PI3K)[23–25]. The molecular nature of 
the GEFs and GAPs regulating RAP1 activity in platelets, however, remained elusive.
The work by Shattil and colleagues was the first to suggest an important role for the 
calcium-sensing GEF, CalDAG-GEFI (Rasgrp2), in RAP1 activity regulation in platelets. 
Using ES cell-derived megakaryocytes they demonstrated a good correlation between the 
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expression level of this candidate protein and RAP1 and integrin activation in these 
cells[26]. Shortly after these pioneering studies, we used Caldaggef1 knockout mice to 
establish a fundamental role for CalDAG-GEFI in Ca2+-dependent RAP1 activation in 
platelets[27]. Platelets lacking CalDAG-GEFI exhibited a marked aggregation defect to 
various agonists, including ADP and collagen, while a more robust aggregation response 
was observed in response to stimulation with thrombin. A very similar aggregation profile 
was recently described for human platelets isolated from patients with severe bleeding due 
to a point mutation in the catalytic GEF domain of CalDAG-GEFI[28].
CalDAG-GEFI is the predominant platelet RAP-GEF and the only member of the RASGRP 
family to be expressed in the platelet/megakaryocytic lineage (Fig.1)[7, 29]. RASGRPs 
typically consist of a N-terminal catalytic GEF domain and a C-terminal regulatory region 
comprising a pair of EF hand domains and a C1 domain (Fig.2). However the catalytic 
specificity and the activity regulation of CalDAG-GEFI are the most divergent within this 
family, as CalDAG-GEFI has RAP, but not RAS, exchange activity in vivo[30], and 
structural rearrangements induced by the binding of Ca2+ to the EF domains are critical for 
its activation[31]. The EF hand domains have very high affinity for Ca2+ (KD~80nM)[31] 
and thus provide remarkable sensitivity towards minor changes in the cytoplasmic Ca2+ 
concentration, which in resting platelets was measured at ~20–50nM. The C1 domain, 
however, is insensitive to the second messenger diacylglycerol (DAG)[32, 33], but it 
contributes to optimal CalDAG-GEFI-dependent RAP1 activation by a hitherto unknown 
mechanism[21]. Platelets from Caldaggef1−/− mice[27] or from patients expressing an 
inactive CalDAG-GEFI mutant[28] a) failed to aggregate in response to calcium ionophore, 
while they reacted to the DAG mimetic PMA (phorbol 12-myristate 13-acetate), b) did not 
respond to threshold doses of physiological agonists (lack of sensitivity) and c) exhibited a 
delayed activation response to high doses of strong agonists (lack of speed). Rapid agonist-
induced elevation in cytosolic Ca2+ concentrations is what drives near-immediate platelet 
activation, which is essential for efficient platelet adhesion in the presence of hemodynamic 
shear forces. Thus platelets lacking the sensitivity and speed provided by CalDAG-GEFI 
failed to form three-dimensional thrombi particularly at arterial shear rates, and 
Caldaggef1−/− mice were strongly protected from FeCl3-induced carotid artery 
thrombosis[21] and collagen-[27] or immune complex-induced[34] pulmonary embolism. 
However a defective CalDAG-GEFI-dependent pathway does not prevent platelet activation 
completely. Both mouse and human platelets lacking functional CalDAG-GEFI could 
undergo a slow but sustained activation that supported the formation of small three-
dimensional thrombi at conditions of low shear flow conditions, such as those found in the 
venous system[21]. This residual RAP1 activation was inhibited by antagonists of PKC or 
P2Y12. An important element of this CalDAG-GEFI-independent pathway was discovered 
very recently (see below).
The RAP-GAP RASA3: a critical inhibitor of platelet activation and the 
missing link in the P2Y12-RAP1 signaling pathway
Important information on the molecular nature of this missing RAP1 regulator came from 
unbiased studies of the platelet proteome and transcriptome[7, 29, 35, 36]. These studies 
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demonstrated that the most abundant RAP-GAP in platelets (Fig.1) is a protein called 
RASA3 (also known as GAP1IP4BP, GAPIII, R-Ras GAP). RASA3 was originally purified 
from the plasma membrane of human platelets in 1994[37] but its role in platelet biology 
was elucidated only recently with studies in transgenic mouse models[38].
RASA3 belongs to a subfamily [39] of four GAP1 proteins (GAP1m/RASA2, RASA3, 
RASAL1 and CAPRI/RASA4) structurally characterized by a GAP domain flanked N-
terminally by two tandem C2 domains and C-terminally by a pleckstrin homology domain 
linked to a 26 amino acid Btk motif (PH/Btk) (Fig.2). The catalytic domain is a conventional 
RAS-GAP domain but it is capable of stimulating the GTPase activity of both RAS- and 
RAP-GTPases depending on the cellular context [40]. This catalytic plasticity is mediated 
by the N- and C-terminal flanking regions, which orient the RAP-GTP catalytic residues in a 
way that allows RAP to hijack the RAS-GAP catalytic machinery[41, 42]. The C2 domains 
of RASA3 are non-canonical and thus do not bind Ca2+ or phospholipids[43]. They have 
currently no other known function besides their essential role in support of the RAP-GAP 
activity. On the contrary, the PH/Btk domain, in addition to its steric role in the catalytic 
reaction, is crucial for RASA3 plasma membrane localization and is presumed to 
dynamically regulate the GAP activity in response to cellular stimulation[44].
The PH/Btk domain of RASA3 is unique as it binds with similarly high affinity to 
phosphatidylinositol 4,5-diphosphate (PIP2) (KD=0.8±0.5 μM) and phosphatidylinositol 
3,4,5-triphosphate (PIP3) (KD=0.5±0.2 μM). PIP2 is abundant in the plasma membrane of 
both resting and activated cells and mediates RASA3 constitutive localization to this 
membrane compartment[44]. PIP3 is the catalytic product of PI3K-mediated 
phosphorylation of PIP2. PIP3 can drive plasma membrane localization of an engineered 
RASA3 unable to bind PIP2[45]. It is not yet clear if and how PIP3 regulates RASA3 GAP 
activity. Since RASA3 binds with high affinity also the water-soluble cognate head group of 
PIP3, inositol 1,3,4,5-tetrakisphosphate (IP4), it has been argued that its GAP activity may 
be regulated by a competition between the binding of IP4 and membrane 
phosphoinositides[46]. However RASA3 has been shown to localize exclusively to the 
plasma membrane, even in conditions where IP4 concentrations are high[44]. Thus the most 
likely regulatory mechanism of RASA3 involves PIP3 and does not require membrane 
detachment. Recent studies, employing two-color super-resolution imaging, have shown that 
PIP2 and PIP3 cluster into distinct membrane microdomains[47]. Future studies need to 
address if PIP2/PIP3-mediated regulation of RASA3 involves compartmentalization into 
different sub-regions of the plasma membrane and/or conformational changes of the protein.
To investigate its role in platelet biology, we generated mice with deletion of Rasa3 in the 
platelet/megakaryocyte lineage[38]. Unexpectedly, these mice exhibited a high embryonic/
neonatal lethality, similar to that observed in germline knockout mice[38] or mice 
expressing a catalytically inactive mutant of the protein (Rasa3ΔGAP)[48]. Thus, while 
studies in the Rasa3ΔGAP mice suggested that the high lethality might be caused by a defect 
in vascular cells, our studies favour a critical role for RASA3 in platelets/megakaryocytes 
during embryonic development. Consistent with this conclusion, we found that Rasa3 
knockout mice are severely thrombocytopenic and that knockout embryos exhibit a marked 
vascular mixing phenotype, similar to that observed in other mouse models of severe 
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thrombocytopenia or impaired platelet function[49]. To understand the cause of the 
thrombocytopenia and the role of RASA3 in platelets, our group employed a mutant mouse 
strain (Rasa3hlb) derived from a forward genetic screen in C57BL/6 mice, which is 
characterized by a single point mutation (H794L) in the C-terminal region of RASA3[38]. 
Platelets from Rasa3hlb homozygous mice exhibit a markedly reduced RASA3 protein level 
and a hypomorphic phenotype, characterized by Mendelian birth rates and a severe, but 
incomplete, thrombocytopenia (29±18 × 103 platelets/μl). Compared to controls, the few 
Rasa3hlb mutant platelets present in circulation were younger and bigger in size, had a short 
half-life and, consistently with the role of RASA3 as a RAP-GAP, had elevated RAP1 and 
integrin activation both at baseline and in stimulated conditions. The latter observation 
prompted us to cross Rasa3hlb mice with mice lacking CalDAG-GEFI, a major regulator of 
RAP1 activation in platelets. Deletion of CalDAG-GEFI reverted the platelet phenotype in 
Rasa3hlb mice, including the pre-activated state, the high turnover, and the severe 
thrombocytopenia. In contrast to studies in Rasa3ΔGAP mice[50], we did not find any gross 
abnormalities in the morphology of MKs and in their ability to form pro-platelets.
The studies outlined above suggest that RASA3 is critical to maintain circulating platelets in 
a quiescent, non-adhesive state. At sites of vascular injury, however, this negative feedback 
would be a liability for platelets during hemostatic plug formation. Thus, we speculated that 
RASA3 activity is downregulated during platelet activation, and that the required signal is 
provided by the CalDAG-GEFI-independent, PKC/P2Y12-dependent signaling pathway 
(see above). Consistent with this hypothesis, we observed that Rasa3 mutant platelets do not 
require feedback activation via the P2Y12 pathway, and that their ability to aggregate is not 
affected by inhibitors of P2Y12[38]. Interestingly, RAP1-dependent integrin activation in 
Rasa3 mutant platelets was also insensitive to inhibitors of PI3K[38], suggesting that 
conversion from PIP2 to PIP3, mediated by PI3K, is critical in the activity regulation of this 
important RAP-GAP.
Model of RAP1-dependent platelet regulation
In summary, these studies demonstrate that a tight regulation of the antagonistic balance 
between the RAP1 regulators, CalDAG-GEFI and RASA3, is critical for both the prevention 
of premature platelet activation in circulation as well as for hemostatic plug formation at 
sites of vascular injury. In platelets that patrol healthy vessels, active RASA3 in the plasma 
membrane is required to antagonize the highly sensitive CalDAG-GEFI/RAP1 signaling 
module and to maintain the cells in a quiescent state (Fig.3, left panel). Upon vascular 
injury (Fig.3, central panel), platelet stimulation via GPCRs and ITAM-coupled receptors 
results in increased levels of cytosolic Ca2+ and the release of ADP from storage granules. 
CalDAG-GEFI is activated by small changes in the cytosolic Ca2+ concentration, leading to 
the rapid activation of RAP1 and αIIbβ3 integrin. CalDAG-GEFI signaling, however, is 
reversible and returns to baseline when cytosolic Ca2+ levels normalize. Thus, to sustain 
integrin activation and to facilitate hemostatic plug formation, RASA3 activity must be 
reduced as part of the activation response. The required signal is provided upon ADP 
engagement of the P2Y12 receptor and signaling by PI3K. Finally, our studies suggest that 
inhibitors of P2Y12, such as clopidogrel bisulfate, protect from thrombosis and impair 
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hemostasis primarily by preventing the inactivation of RASA3 and thus prohibiting 
sustained RAP1 signaling (Fig.3, right panel).
There are many unanswered questions concerning RAP1 signaling in platelets. For example, 
it will be interesting to see if and how platelet function is affected by RAP GEFs and GAPs 
other than CalDAG-GEFI and RASA3, which are expressed at low levels in these cells. 
Important information is also missing with regard to the activity regulation of CalDAG-
GEFI and RASA3 by engagement of their regulatory domains or posttranslational 
modifications within these proteins. As for RAP itself, it will be interesting to determine if 
there are functional redundancies as well as unique contributions of the various RAP 
isoforms to platelet activation, and which protein effectors link RAP to its downstream 
platelet responses, especially talin-dependent integrin activation.
In addition to these more fundamental questions, we need more studies on the clinical 
relevance of alterations in platelet RAP1 signaling. For example, some inherited disorders of 
platelet function or number may, at least in part, be explained by gene variations in key 
players of the RAP pathway. Platelet hypo- or hyper-reactivity observed among individuals 
or as a result of certain disease states may be the result of inter-individual or acquired 
variability in the antagonistic balance between CalDAG-GEFI and RASA3 (expression 
and/or activity). If successful these studies could pave the way to novel and more 
personalized approaches to anti-platelet therapy.
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Fig.1. RAS/RAPs, GEFs and GAPs protein expression in platelets
Estimated protein levels based on the most comprehensive quantitative proteomic analysis 
of human[7] (full bars) and mouse[29] (striped bars) platelets. CalDAG-GEFI and RASA3 
are the most abundant RAP regulators expressed in both human and mouse platelets.
Stefanini and Bergmeier Page 10
J Mol Med (Berl). Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig.2. Domain structure of the RAP1 regulators, CalDAG-GEFI and RASA3
CalDAG-GEFI consists of a RAP-specific catalytic guanine nucleotide exchange factor 
(GEF) domain, a pair of Ca2+ binding EF hand domains (EF) and a C1-like domain of 
hitherto unknown function that is necessary for optimal RAP-GEF activity. RASA3 consists 
of a catalytic GTPase-activating protein (GAP) domain specific for RAS and RAP, flanked 
by a pair of C2 domains and by a PH/Btk domain that binds phosphatidylinositol 4,5-
diphosphate (PIP2) and phosphatidylinositol 3,4,5-triphosphate (PIP3). The Rasa3hlb mutant 
mouse strain is characterized by a single point mutation (H794L) in the C-terminal region of 
RASA3. GTP (guanosine triphosphate), GDP (guanosine diphosphate).
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Fig.3. Schematic model of RAP1-dependent platelet regulation
Left panel. In platelets circulating healthy vessels RASA3 is active to restrain uncontrolled 
RAP1 activation and maintain a quiescent, non-adhesive state (no integrin activation). 
Central panel. At sites of vascular injury, platelets stimulation results in an increase in the 
cytosolic Ca2+ levels and the release of ADP from dense granules. Ca2+ activates CalDAG-
GEFI, which mediates rapid GTP-loading of RAP1. ADP stimulates the P2Y12 receptor, 
which leads to decreased RASA3 function and sustained RAP1 signaling. Fast and sustained 
RAP1/integrin activation results in the formation of stable three-dimensional thrombi over a 
broad range of hemodynamic shear conditions. Right panel. Inhibitors to P2Y12, such as 
Clopidogrel, prevent the inactivation of RASA3, prohibit sustained RAP1 signaling and 
destabilize the growing thrombus.
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